Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | GPR52 | Q9Y2T5 | 7/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5202349 | 0.87 | STAT3 (0.43) | TRPV3 | |
| SCHEMBL5207531 | 0.81 | RAB9A (0.46) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL5202727 | 0.78 | TRPV3 (0.46) | CYP1A2TRPV3 | |
| SCHEMBL6182752 | 0.73 | NPSR1 (0.55) | CYP1A2CYP2C9CYP2C19RAB9A | |
| SCHEMBL8871754 | 0.73 | GPR52 (0.42) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL5209985 | 0.73 | HSP90AA1 (0.39) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL5204620 | 0.72 | LMNA (0.45) | TRPV3 | |
| SCHEMBL5203501 | 0.72 | CNR2 (0.51) | CYP1A2CYP3A4 | |
| SCHEMBL14983666 | 0.71 | IDO1 (0.47) | GRIN2B | |
| SCHEMBL5219754 | 0.70 | LMNA (0.43) | RAB9ATRPV3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1036066-B1 | SUBSTITUTED PYRIMIDINE AND PYRIDINE HERBICIDES | MID AMERICA COMMERCIALIZATION (US) | 2007-04-18 | — | — | EP | claimed |
| US-20040033896-A1 | E.g., 5-ethyl-4-((3 -(trifluoromethoxy)phenyl)methyl)-2-(3-(trifluoromethyl)-1H pyrazol-1-yl)pyrimidine and 5-methyl-2-(4-(trifluoromethyl)phenyl)-4-((3-(trifluoromethyl) phenyl)methyl)pyrimidine | KOETHER GERARD (US) | 2004-02-19 | — | — | US | claimed |
| US-6525001-B1 | 5-methyl-2-(4-(trifluoromethyl)phenyl)-4-((3 -(trifluoromethyl)phenyl)methyl)pyrimidine | MID-AMERICAN COMMERCIALIZATION CORPORATION | 2003-02-25 | — | — | US | claimed |
| EP-1036066-A1 | SUBSTITUTED PYRIMIDINE AND PYRIDINE HERBICIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2000-09-20 | — | — | EP | claimed |
| WO-1999028301-A1 | SUBSTITUTED PYRIMIDINE AND PYRIDINE HERBICIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1999-06-10 | — | — | WO | claimed |
| EP-1036066-B1 | SUBSTITUTED PYRIMIDINE AND PYRIDINE HERBICIDES | MID AMERICA COMMERCIALIZATION (US) | 2007-04-18 | — | — | EP | disclosed |
| US-20040033896-A1 | E.g., 5-ethyl-4-((3 -(trifluoromethoxy)phenyl)methyl)-2-(3-(trifluoromethyl)-1H pyrazol-1-yl)pyrimidine and 5-methyl-2-(4-(trifluoromethyl)phenyl)-4-((3-(trifluoromethyl) phenyl)methyl)pyrimidine | KOETHER GERARD (US) | 2004-02-19 | — | — | US | disclosed |
| US-6525001-B1 | 5-methyl-2-(4-(trifluoromethyl)phenyl)-4-((3 -(trifluoromethyl)phenyl)methyl)pyrimidine | MID-AMERICAN COMMERCIALIZATION CORPORATION | 2003-02-25 | — | — | US | disclosed |
| EP-1036066-A1 | SUBSTITUTED PYRIMIDINE AND PYRIDINE HERBICIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2000-09-20 | — | — | EP | disclosed |
| WO-1999028301-A1 | SUBSTITUTED PYRIMIDINE AND PYRIDINE HERBICIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1999-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040033896-A1 | E.g., 5-ethyl-4-((3 -(trifluoromethoxy)phenyl)methyl)-2-(3-(trifluoromethyl)-1H pyrazol-1-yl)pyrimidine and 5-methyl-2-(4-(trifluoromethyl)phenyl)-4-((3-(trifluoromethyl) phenyl)methyl)pyrimidine | PYM1, Q6ZSR9, MRM1 | CYP1A2 429/4885CYP3A4 724/4885CYP2D6 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.